summary Anti CD20 antibody immunotherapy eŠectively treats non-Hodgkin's lymphoma and autoimmune disease. However, the cellular and molecular pathways for B cell depletion remain undeˆned and the in vivo eŠect of immunotherapy on tissue B cells and their subsets is generally unknown. To identify the mechanisms for B cell depletion in vivo, a new mouse model for anti CD20 immunotherapy was developed using a panel of twelve mouse anti-mouse CD20 monoclonal antibodies. Anti CD20 antibodies rapidly depleted the vast majority of circulating and tissue B cells in an isotype-restricted manner that was completely dependent on eŠector cell Fc receptor expression. B cell depletion utilized FcgRI , FcgRIIIand FcgRIV dependent pathways, while B cells were not eliminated in FcR common g chaindeˆcient mice. Monocytes were the dominant eŠector cells for B cell depletion, with no demonstrable role for T or NK cells. Although most anti CD20 antibodies activated complement in vitro, B cell depletion was completely eŠective in mice with genetic deˆciencies in C3 complement components. The considerable factors that determine the eŠectiveness of anti CD20 immunotherapy are following: the expression level of CD20 on B cell surface; the dosage of anti CD20 mAb; the association of Fcg receptor with the isotype of the antibies; B cell subpopulations within diŠerent tissues. Theseˆndings have important clinical implications for anti CD20 and other antibody-based therapies. 
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障害活性（Antibody-dependent cellular cytotoxity : 
